Advaxis Combination Trial with Merck Completes First Two Dose-Escalation Cohorts
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Wall St eyes best day in a month as Anthropic's IPO filing propels AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
| ADVAXIS (AMEX: ADXS) | Delayed: 0.60 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.60 | 52 Week High | $16.30 | |||
| Open | $0.60 | 52 Week Low | $5.21 | |||
| Day High | $0.60 | P/E | N/A | |||
| Day Low | $0.60 | EPS | $-4.10 | |||
| Volume | 6,221,965 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 141.48 -3.79 (2.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $145.27 | 52 Week High | $65.46 | |||
| Open | $145.89 | 52 Week Low | $47.97 | |||
| Day High | $146.61 | P/E | 96.24 | |||
| Day Low | $141.18 | EPS | $1.47 | |||
| Volume | 3,855,224 | |||||
